K-757 is under clinical development by Kallyope and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how K-757’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

K-757 overview

K-757 is under development for the treatment of metabolic disorders such as obesity (weight loss) in patients with type 2 diabetes. The drug candidate acts by targeting the circuits involved in the gut-brain axis. It is administered through oral route. It is developed based on computational biology. It acts by targeting GPR40.

Kallyope overview

Kallyope is a biotechnology company identifying therapeutics targeting the gut-brain axis. The company undertakes a systems biology approach by utilizing an integrated platform to identify gut-brain circuits compasses in physiology, behavior and defects of biological systems in multiple diseases. Kallyope integrates cutting-edge technologies in bioinformatics, sequencing, cellular and molecular biology, human genetics and neural imaging for understanding gut-brain biology and develops gut-restricted molecules to improve human health. It also offers solutions for diabetes, obesity, inflammatory disease, migraine, and allergies. Kallyope is headquartered in New York City, New York, the US.

For a complete picture of K-757’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.